Because of tumor-to-blood drug concentration asymmetry, A947 showed dose-dependent tumor growth inhibition in the HCC2302 xenograft model after weekly doses of 20 mg/kg or 40 mg/kg (Fig. 5, Supplementary Tables 10–13), which was accompanied by a dose-dependent pharmacodynamic effect on the KRT80 transcript (46% vs 69% suppression, p = 0.0036, Table 2). This evidence concerns the gene KRT80 and neoplasm.